|
|
ACE Inhibitor Efficacy (ACE, thrombophilia association marker) |
PHGN |
|
|
Signs/symptoms: |
Efficacy of statins and gemfibrozil in hyperlipidemia, efficacy of betablocker in heart failure, efficacy of ACE inhibitors. |
|
Complications: |
Hyperlipidemia, hypertension. |
|
Early diagnosis/treatment: |
Yes |
|
|
|
Material required: |
|
Blood tubes: |
EDTA whole blood (do not freeze, do not centrifugate) |
|
Mouth brush: |
No |
|
|
|
|
|
Chromosomal localization: |
17q23 |
OMIM number: |
106180 |
|
Angiotensin I converting enzyme (insertions/deletions polymorphism) |
ACE |
|
Gene regions tested: |
|
Gene regions: |
|
|
|
Amino acid positions: |
insertion/deletion polymorphism |
|
Nucleotide positions: |
|
|
Test methods: |
Sequencing |
|
|
|
|
|
|
|
| |
TP REVAL: |
250 |
TP Value: |
0.9 |
CHF |
225.00 |
|
Other europe: |
EUR |
160.00 |
|
Other regions: |
USD |
call |
|
|
|
| Seckin D, Ilhan N, Ilhan N, Ozbay Y. The relationship between ACE insertion/deletion polymorphism and coronary artery disease with or without myocardial infarction. Clin Biochem. 2006;39:50-54. | |
| Maitland-van der Zee AH, Stricker BH, Klungel OH, Kastelein JJ, Hofman A, Witteman JC, Leufkens HG, Duijn CM, Boer Ad A. Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis. 2004;175:377-379. | |
| McNamara DM, Holubkov R, Janosko K, Palmer A, Wang JJ, MacGowan GA, Murali S, Rosenblum WD, London B, Feldman AM. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 2001;103:1644-1648. | |
| Bosse Y, Vohl MC, Dumont M, Brochu M, Bergeron J, Despres JP, Prud'homme D. Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. Clin Genet. 2002;62:45-52. | |
